ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents AI-driven digital twin for simulation of aging eye
The Virtual Eye Simulation Analyzer is an AI-driven digital twin of the human eye designed to model aging and personalize presbyopia treatment across the lifecycle.
AnnMarie Hipsley, DPT, PhD, presented a transformative concept in ophthalmic innovation: the “digital twin” of the human eye, embodied in the Virtual Eye Simulation Analyzer (VESA)—a virtual, AI-driven model capable of simulating the anatomy and aging of the eye—at the 2025 American Society of Cataract and Refractive Surgery annual meeting, held April 25 to 28 in Los Angeles, California. A digital twin is a virtual representation of a physical entity, and in this case, VESA was developed over the past decade to model the full lifecycle of presbyopia.
Originally designed to explore treatment options from early to advanced stages of presbyopia, VESA creates a personalized 3D ID using topography, refractive data, and the material properties of ocular tissues. “It becomes a representation of a person’s eye,” Hipsley explained. In this study, a 52-year-old eye served as the baseline model, chosen for its biomechanical stability. Leveraging Ansys and proprietary physics-based modeling, VESA simulated changes in dioptric power, lens accommodation, and structural shifts in the sclera, lens, Bruch’s membrane, and zonular fibers.
VESA’s next step: simulation of personalized treatments tailored to specific ages and anatomical profiles. “VESA was able to calculate and spit out precision patterns for each of those stages and ages,” Hipsley said. The system’s predictive capacity opens doors to virtual IOL implantation and treatment planning, allowing innovators to “test your innovation virtually… and come up with fail-fast answers” before entering clinical trials.
With patient data stored securely on a 3D ID card, the system supports longitudinal care and privacy. “Every single patient becomes 1000 simulations of data,” Hipsley noted, positioning VESA as a future-forward tool for real-time clinical updates, predictive diagnostics, and a major step toward individualized, minimally invasive ophthalmic care.
Explore More Articles
Laser scleral microporation helps turn back the clock for presbyopic eyes
VIENNA — In this Healio Video Perspective from the ESCRS meeting, Robert Ang, MD, shares his results with laser scleral microporation for the treatment of presbyopia. He explains the rationale of laser scleral microporation (Ace Vision Group), how it is performed, and the advantages of a treatment that does not interfere with the visual axis and allows the …
read moreRobert Ang Discusses LSM by Ace Vision
Robert T. Ang, refractive surgeon at the Asian Eye Institute in the Philippines, talks to The Ophthalmologist about the ways Laser Scleral Microporation (LSM) therapy offered by Ace Vision Group comes to benefit him and his patients. He discusses the therapy’s mechanism of action, what the procedure involves, and the unique value offered by LSM. …
read moreThe Future of the Aging Eye
AnnMarie Hipsley, the Founder and CEO of Ace Vision Group (AVG), a Delaware, USA- based company developing innovative therapeutics for age-related ocular dysfunctions, talks to The Ophthalmologist about her background and work with AVG, and the company’s short- and long-term goals. She explains how the Group has utilized artificial intelligence and virtual reality platforms to …
Show video